A new study presented at the American College of Rheumatology (ACR) Convergence 2025 has given hope to millions of people living with rheumatoid arthritis (RA). It suggests that some medicines originally developed for diabetes and weight loss might also help reduce joint pain and inflammation in RA patients. However, doctors are advising everyone to stay cautious until more research confirms these early findings.
Researchers studied a group of patients who already had rheumatoid arthritis and were taking standard treatments, such as disease-modifying antirheumatic drugs (DMARDs). Among these patients, some were also prescribed a newer class of drugs known as GLP-1 receptor agonists, which are commonly used for diabetes and weight management. A few patients were also taking SGLT-2 inhibitors, another type of diabetes medication.
The results were interesting. Patients who used GLP-1 receptor agonists showed fewer flare-ups of arthritis, less inflammation, and better overall health compared to those who were not taking these drugs. According to the researchers, these patients had fewer painful episodes and showed improvements in blood tests that measure inflammation.
In one study involving 173 rheumatoid arthritis patients with an average Body Mass Index (BMI) of 27, those who took a GLP-1 drug for one year showed a 32% improvement in disease activity. The other group, who did not take the drug, showed only a 17% improvement. The group on GLP-1 drugs also lost more weight—around 4.4 kilograms compared to just 1.2 kilograms in the control group.
Doctors also noticed better results in other health markers such as cholesterol levels and C-reactive protein (CRP), which is a key sign of inflammation in the body. These positive changes hint that GLP-1 drugs may reduce overall inflammation, which could ease rheumatoid arthritis symptoms.
ALSO READ: Good fat, bad fame: Doctor debunks six biggest myths about cholesterol
ALSO READ: How Noida International Airport is set to redefine travel and trade across northern India
Rheumatoid arthritis is not just a joint disease — it is an autoimmune condition. This means that the body’s immune system mistakenly attacks its own tissues, especially the joints, leading to pain, swelling, and stiffness. But RA also affects other systems in the body. It is often linked to metabolic problems like obesity, insulin resistance, and heart disease.
This is where diabetes and weight-loss drugs come into the picture. GLP-1 receptor agonists, such as semaglutide and liraglutide, help regulate blood sugar levels, reduce appetite, and promote weight loss. They also help improve the body’s response to insulin and reduce inflammation in blood vessels.
Scientists believe that by improving metabolism and lowering inflammation, these drugs might also reduce the immune system’s overactive response seen in RA. Simply put, when the body becomes less inflamed overall, the joints may also feel less painful and swollen.
Another possible reason is that weight loss itself benefits people with arthritis. Carrying less weight reduces pressure on the joints, improves mobility, and helps medications work better. So, it’s possible that part of the benefit seen in the study comes from the weight loss these drugs provide, rather than a direct effect on the immune system.
While the study’s results sound promising, doctors warn that the research is still at an early stage. Most of the data so far come from observational studies, which means they show trends but do not prove cause and effect. Larger and more detailed clinical trials are needed before these drugs can be officially recommended for rheumatoid arthritis treatment.
Experts also highlight that rheumatoid arthritis treatment must remain focused on proven therapies such as DMARDs, biologics, and steroids when necessary. These medicines specifically target the immune system’s attack on the joints and are backed by years of research.
Dr. Bhanu Mishra, a rheumatologist not involved in the study, explains, “These new findings are exciting, but people with RA should not stop their prescribed medications. GLP-1 drugs may help in the future, but for now, they should only be used for their approved purposes—mainly diabetes and obesity.”
For patients who have both RA and metabolic problems such as diabetes or obesity, these drugs might become a valuable add-on therapy in the future. But anyone considering them should first discuss the idea with their rheumatologist or physician. Taking them without medical supervision could lead to side effects or interfere with existing treatments.
Rheumatoid arthritis is a complex condition that affects the whole body, not just the joints. Managing it requires a combination of medicine, diet, exercise, and stress control. Even if GLP-1 drugs show promise, lifestyle changes remain just as important.
Here are a few doctor-approved tips for living better with RA:
Maintain a healthy weight: Reducing excess body fat helps lessen pressure on the joints and lowers inflammation.
Eat anti-inflammatory foods: Include fruits, vegetables, omega-3 fatty acids (from fish or flaxseed), and whole grains in your diet.
Stay active: Light exercises like walking, yoga, and swimming can strengthen muscles and reduce stiffness.
Get enough rest: Proper sleep helps control inflammation and keeps the immune system balanced.
Work with your doctor: Regular check-ups ensure your medication is working effectively and side effects are monitored.
In short, the connection between metabolic health and rheumatoid arthritis is becoming clearer. Drugs designed to manage blood sugar and body weight may soon play a role in treating inflammation and joint pain too.
However, experts agree that it is too early to call these drugs a breakthrough for RA. For now, they offer hope — not a cure. Continued research will tell whether this hope turns into a new treatment option for millions of people struggling with the pain and fatigue of rheumatoid arthritis.
Copyright © © 2022 Copyright. All Rights Reserved with Arth Parkash